Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 19;21(14):5097.
doi: 10.3390/ijms21145097.

Galectin-3 in Inflammasome Activation and Primary Biliary Cholangitis Development

Affiliations
Review

Galectin-3 in Inflammasome Activation and Primary Biliary Cholangitis Development

Aleksandar Arsenijevic et al. Int J Mol Sci. .

Abstract

Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune liver disease characterized by inflammation and damage of small bile ducts. The NLRP3 inflammasome is a multimeric complex of proteins that after activation with various stimuli initiates an inflammatory process. Increasing data obtained from animal studies implicate the role of NLRP3 inflammasome in the pathogenesis of various diseases. Galectin-3 is a β-galactoside-binding lectin that plays important roles in various biological processes including cell proliferation, differentiation, transformation and apoptosis, pre-mRNA splicing, inflammation, fibrosis and host defense. The multilineage immune response at various stages of PBC development includes the involvement of Gal-3 in the pathogenesis of this disease. The role of Galectin-3 in the specific binding to NLRP3, and inflammasome activation in models of primary biliary cholangitis has been recently described. This review provides a brief pathogenesis of PBC and discusses the current knowledge about the role of Gal-3 in NLRP3 activation and PBC development.

Keywords: NLRP3; galectin-3; inflammasome; primary biliary cholangitis (PBC).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Gal-3 in inflammasome activation and PBC development. Novosphingobium aromaticivorans infection activates innate immune cells (monocytes/macrophages) and in the presence of Gal-3 (left side) induces NLRP3 inflammasome activation. Activated macrophages produce a large amount of proinflammatory cytokines that activates NK cells and induce adequate activation of dendritic cells that are capable to activate autoreactive T lymphocytes (probably by mechanism of molecular mimicry) and induce their differentiation toward inflammatory Th1 and Th17 phenotype, and stimulate B cells to produce autoantibodies, AMA. Apoptosis of cholangiocytes induced by inflammatory process results in PDC-E2 antigen exposure in apoptotic blebs, which is recognized by produced AMA and results in antigen–antibody complex formation that contributes to cellular injury. Bile duct damage is the result of intrahepatic accumulation of inflammatory Th1 and Th17 cells, inflammatory and cytotoxic CD8 cells, activated, IL-17 producing NK and NKT cells that promote biliary injury, accompanied by autoantigen release that leads to perpetuation of autoimmune process. In the absence of Gal-3 (right side) there is no sufficient inflammasome activation followed by inadequate activation of dendritic cells and later insufficient activation of T and B lymphocytes. There is insignificant liver infiltration with inflammatory T, NK and NKT cells insufficient to trigger autoimmune process, and there is no biliary damage.

References

    1. Hirschfield G.M., Gershwin M.E. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu. Rev. Pathol. 2014;8:303–330. doi: 10.1146/annurev-pathol-020712-164014. - DOI - PubMed
    1. Li Y., Tang R., Leung P.-S.C., Gershwin M.E., Ma X. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. Autoimmun. Rev. 2017;16:885–896. doi: 10.1016/j.autrev.2017.07.002. - DOI - PubMed
    1. Carey E.J., Ali A.H., Lindor K.D. Primary biliary cirrhosis. Lancet. 2015;386:1565–1575. doi: 10.1016/S0140-6736(15)00154-3. - DOI - PubMed
    1. Shimoda S., Tanaka A. It is time to change primary biliary cirrhosis (PBC): New nomenclature from “cirrhosis” to “cholangitis”, and upcoming treatment based on unveiling pathology. Hepatol. Res. 2016;46:407–415. doi: 10.1111/hepr.12615. - DOI - PubMed
    1. Webb G.J., Hirschfield G.M. Primary biliary cholangitis in 2016: High-definition PBC: Biology, models and therapeutic advances. Nat. Rev. Gastroenterol. Hepatol. 2017;14:76–78. doi: 10.1038/nrgastro.2016.201. - DOI - PubMed

LinkOut - more resources